Immuron Limited (IMRN)
- Previous Close
2.5300 - Open
2.4400 - Bid --
- Ask --
- Day's Range
2.4300 - 2.5200 - 52 Week Range
1.4810 - 5.9600 - Volume
1,364 - Avg. Volume
919,248 - Market Cap (intraday)
14.874M - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
www.immuron.com.auRecent News: IMRN
Performance Overview: IMRN
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMRN
Valuation Measures
Market Cap
14.69M
Enterprise Value
2.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.10
Price/Book (mrq)
1.24
Enterprise Value/Revenue
0.72
Enterprise Value/EBITDA
-0.66
Financial Highlights
Profitability and Income Statement
Profit Margin
-108.52%
Return on Assets (ttm)
-9.87%
Return on Equity (ttm)
-20.01%
Revenue (ttm)
3.58M
Net Income Avi to Common (ttm)
-3.88M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
16.42M
Total Debt/Equity (mrq)
0.97%
Levered Free Cash Flow (ttm)
-2.66M